TheraRadar
Data updated: May 26, 2026

LEVOMILNACIPRAN HYDROCHLORIDE

Trial Activity: Declining
CNS Approved 2019-02-04

Levomilnacipran hydrochloride treats major depressive disorder in adult patients. This medication helps patients with depression by increasing the activity of specific chemical signals in the central nervous system. Although it belongs to the serotonin and norepinephrine reuptake inhibitor class, it is not used for managing fibromyalgia.

Source: FDA Label • PRINSTON INC

How LEVOMILNACIPRAN HYDROCHLORIDE Works

This drug works by blocking the reuptake of serotonin and norepinephrine

Source: FDA Label

Development Insights

Forest Laboratories conducting 1 trials (33%)
1 indications explored (Focused)
major depressive disorder (3 trials)
4
Indications
--
Phase 3 Trials
7
Years on Market

Details

Status
Prescription
First Approved
2019-02-04
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

LEVOMILNACIPRAN HYDROCHLORIDE Approval History

2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
40 FDA actions from 2019 to 2025
Jul 2025 SUPPL
Label · Labeling
Mar 2023 ORIGINAL
Update
Jan 2023 SUPPL
Label · Labeling

What LEVOMILNACIPRAN HYDROCHLORIDE Treats

1 indications

LEVOMILNACIPRAN HYDROCHLORIDE is approved for 1 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Major Depressive Disorder
Source: FDA Label

LEVOMILNACIPRAN HYDROCHLORIDE Boxed Warning

SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 ) ] . FETZIMA is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 ) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing infor...

LEVOMILNACIPRAN HYDROCHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 13 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to LEVOMILNACIPRAN HYDROCHLORIDE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

APLENZIN
BUPROPION HYDROBROMIDE
1 shared
BAUSCH
Shared indications:
AUVELITY
BUPROPION HYDROCHLORIDE
1 shared
AXSOME
Shared indications:
CAPLYTA
LUMATEPERONE TOSYLATE
1 shared
INTRA-CELLULAR
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVOMILNACIPRAN HYDROCHLORIDE FDA Label Details

Indications & Usage

LEVOMILNACIPRAN HYDROCHLORIDE is indicated for the treatment of Major Depressive Disorder.

⚠️ BOXED WARNING

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors...

Looking for the branded version?

FETZIMA

Full clinical data, patents, trials, and competitive landscape for levomilnacipran hydrochloride.

See FETZIMA

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment